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 Atypical antipsychotics are used to treat schizophrenia and although atypical 
antipsychotics helped improve the management of positive symptoms, many patients are still 
suffering from negative and cognitive symptoms and side effects. Serotonin-2A receptors have 
been implicated in the mechanism of action of atypical antipsychotics. Atypical antipsychotics 
such as olanzapine and clozapine are antagonists of 5-HT2A/Gαq/11 pathway, but activate the 5-
HT2A/JAK2/STAT3 pathway. Studying the functional selectivity of atypical antipsychotics at 
the 5-HT2A receptor may lead to a better understanding of the role that 5-HT2A receptors play 
in the therapeutic effect of atypical antipsychotics. This dissertation investigates five analogs of 
olanzapine and the 5-HT2A receptor antagonist, ketanserin, for functional selectivity at the 5-
HT2A receptor. A calcium mobilization assay was used to investigate the 5-HT2A/Gαq/11 
pathway and immunoblotting was used to investigate the 5-HT2A/JAK2/STAT3. We identified 
three analogs that induced calcium mobilization and two analogs that prevented 5-HT2A 
receptor agonist induced calcium mobilization. We also found that four analogs induced 
phosphorylation of JAK2 and one analog that prevented 5-HT2A receptor agonist induced 
phosphorylation of JAK2. In the future, functionally selective analogs can be used to study the 5-
HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 pathways separately in order to gain a better 
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Chapter 1: Introduction 
Schizophrenia  
Schizophrenia is a debilitating psychological disorder that affects approximately 1% of 
the population. Symptoms of schizophrenia can be divided into positive, negative, and cognitive 
symptoms. Positive symptoms include delusions, hallucinations, and an overall loss of reality. 
Negative symptoms include dramatic changes to personality, impaired motivation, social 
isolation, emotional dysregulation, and disorganized behavior. Cognitive symptoms include 
attention and memory deficits as well as disturbances in thought processes (Joyce and Roiser 
2007, Owen, Sawa et al. 2016). The onset of symptoms usually occurs between the ages of 16-
25, but because these symptoms vary between patients, schizophrenia is often difficult to 
diagnose. In addition, schizophrenia is a chronic disorder and the manifestation of symptoms can 
change throughout a patient’s lifespan (Lieberman, Perkins et al. 2001, Addington and Heinssen 
2012). 
Currently, the cause for schizophrenia is unknown, but it is hypothesized that 
schizophrenia could be due to a combination of molecular, cellular, and/or structural 
abnormalities in the brain (NIMH 2016). Although there is an increased risk of schizophrenia 
when family members also have the disorder, there are currently no genetic biomarkers that can 
definitively identify people who will develop schizophrenia (Fullard, Halene et al. 2016). 
Environmental factors such as stresses during early neurodevelopment, socioeconomic factors, 
childhood trauma, brain injuries, infections, drug use and other disorders (such as epilepsy) have 
correlated to an increased risk of schizophrenia (Kunugi, Urushibara et al. 2003, Khandaker, 




There are studies to support that irregularities in neurotransmission may play a role in the 
manifestation of symptoms. For example, dysfunction of dopaminergic signaling is implicated in 
psychotic symptoms (Creese, Burt et al. 1976, Abi-Dargham 2014). There are also theories that 
glutamatergic dysfunction could contribute to cognitive symptoms of schizophrenia 
(Moghaddam and Javitt 2012). Alterations of N-methyl-D-aspartate (NMDA) glutamate 
receptors can lead to impaired synchronization of neuronal firing, thus leading to impaired 
cognitive function (Kantrowitz and Javitt 2010). Irregularities of serotonergic signaling may also 
contribute to altered function seen in schizophrenia (Meltzer, Li et al. 2003, Aznar and Hervig 
Mel 2016). 
Cellular stress is theorized to contribute to the pathology of schizophrenia. Stress 
associated signaling pathways, such as those related to inflammatory responses and oxidative 
stress, normally regulate the development and maintenance of synaptic connectivity, but in 
schizophrenic patients there are abnormalities in interneurons and dendritic spines (Schafer, 
Lehrman et al. 2012, Ji, Miyauchi et al. 2013). There is evidence that oxidative stress may be 
causing deficits in myelination needed for signal transduction (Cabungcal, Counotte et al. 2014, 
Sawa and Seidman 2014). Altered inflammatory responses could be contributing to dysfunction 
of astrocytes and microglia that are known to maintain dendritic spines (Owen, Sawa et al. 
2016).  
Antipsychotics  
There is currently no cure for schizophrenia and management of symptoms depends on 
antipsychotics and psychotherapy. First generation antipsychotics, also known as typical 
antipsychotics, were developed in the 1950s after it was discovered that chlorpromazine could 




receptors (Shen 1999, Seeman 2010). More potent typical antipsychotics, such as haloperidol, 
loxapine, and perphenazine, were developed in the 1960s and 1970s to antagonize dopamine D2 
receptors. The first generation antipsychotics were effective in managing positive symptoms 
such as delusions and hallucinations in some patients, but were accompanied by severe 
extrapyramidal side effects such as Parkinsonism, akathisia, acute dystonia, and tardive 
dyskinesia (Barnes and McPhillips 1998, Llorca, Chereau et al. 2002). Due to the debilitating 
side effects and ineffective treatment of negative and cognitive symptoms, the second generation 
antipsychotics were created.  
Second generation antipsychotics, also known as atypical antipsychotics, are also 
antagonists of dopamine D2 receptors, but this antagonism is no longer the only therapeutic 
target. Atypical antipsychotics also antagonize dopamine D1 and D4 receptors as well as 
histaminergic, muscarinic, and serotoninergic receptors (Bymaster, Calligaro et al. 1996, Arnt 
1998). Because of these diverse interactions, atypical antipsychotics were more effective in 
improving positive symptoms and patients also reported improvements of negative and cognitive 
symptoms. The extrapyramidal side effects of atypical antipsychotics were greatly reduced 
compared to typical antipsychotics, however atypical antipsychotics have other side effects such 
as weight gain, metabolic syndrome, diabetes, sexual dysfunction, and cardiovascular disease 
(Ucok and Gaebel 2008). Researchers have hypothesized that the improved management of 
negative and cognitive symptoms could be due to interaction with serotonin receptors (Meltzer 
1999, Amato 2015).  
Atypical antipsychotics, such as olanzapine and clozapine, antagonize serotonin 
receptors, such as serotonin-2A and 2C receptors. Atypical antipsychotics can lead to 




suggested that this effect on 5-HT2A receptors could be contributing to the antipsychotic effects 
(Meltzer, Li et al. 2003, Amato 2015).  
Serotonin Receptors 
The neurotransmitter serotonin (5-HT) and serotonin receptors modulate a number of 
behavioral processes such as mood, perception, aggression, memory, sexuality, and attention 
(Berger, Gray et al. 2009). There are seven families of serotonin receptors, 5-HT1-5HT7 
receptors. The family of 5-HT1 receptors contain five receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-
HT1E, and 5-HT1F (Hoyer, Clarke et al. 1994). 5-HT1 receptors are G-protein coupled receptors 
(GPCRs) that negatively regulate adenylyl cyclase and cAMP (Polter and Li 2010). The 5-HT3 
receptor is the only 5-HT receptor that is an ionotropic receptor and activation of the receptor 
causes depolarization through the opening of cation channels (Costall and Naylor 2004). 5-HT4, 
5-HT6, and 5-HT7 are GPCRs that couple to Gαs proteins that positively regulate adenylyl 
cyclase and cAMP (Berger, Gray et al. 2009). The 5-HT5 receptor has not been thoroughly 
characterized, but it is thought to be similar to 5-HT1 receptors (Hoyer, Clarke et al. 1994).  
5-HT2A Receptors 
In the family of 5-HT2 receptors, there are three receptors: 5-HT2A, 5-HT2B, and 5-
HT2C (Eison and Mullins 1996). The three subtypes have a 45-50% sequence identity and the 
transmembrane domains of 5-HT2A and 5-HT2C receptors share 80% of their sequence 
(Blaazer, Smid et al. 2008). 5-HT2A receptors are pleiotropic GPCRs expressed within regions 
of the brain including the cortex, the claustrum, entorhinal and piriform cortices, the basal 
ganglia, and the hippocampus (Barnes and Sharp 1999). The receptor is also found in blood 
platelets, smooth muscle, and skeletal muscle (Cook, Fletcher et al. 1994, Fiorica-Howells, Hen 




GABAergic interneurons, and cholinergic neurons (Blaazer, Smid et al. 2008). 5-HT2A 
receptors in the central nervous system (CNS) can modulate GABAergic and glutamatergic 
neurotransmission, the secretion of hormones, and neuronal plasticity (Vaidya, Marek et al. 
1997, Van de Kar, Javed et al. 2001, Leysen 2004). In the periphery, vasoconstriction and 
platelet aggregation are regulated by 5-HT2A receptors (Leysen, de Chaffoy de Courcelles et al. 
1984). 
The 5-HT2A receptor has been implicated in schizophrenia, depression, anxiety, 
obsessive compulsive disorders (OCD), and attention deficit hyperactivity disorder. In 
postmortem studies of depressed patients and patients who have committed suicide, 5-HT2A 
receptors were increased in the brain (Dwivedi, Mondal et al. 2005). Likewise, patients with 
OCD show increased 5-HT2A receptor binding (Adams, Hansen et al. 2005). In the postmortem 
studies of schizophrenic patients, 5-HT2A receptors are decreased in the cortex (Bennett, Enna et 
al. 1979, Matsumoto, Inoue et al. 2005). Therefore, the receptor is a target for antipsychotics, 
antidepressants, and other therapeutic drugs. In animal studies, antidepressants have been shown 
to decrease 5-HT2A receptors in the brain, suggesting a role of 5-HT2A in the action of 
antidepressants. As stated before, atypical antipsychotics bind to the 5-HT2A receptor, as well as 
hallucinogens that produce schizophrenic-like symptoms, indicating a relationship between 5-
HT2A receptors and schizophrenia (Muschamp, Regina et al. 2004).  
Signaling Pathways of 5-HT2A Receptors 
The 5-HT2A receptors are GPCRs that have seven-transmembrane structures that couple 
to G-proteins. Like the other members of the 5-HT2 subfamily, the 5-HT2A receptor couples 
with Gαq/11 proteins to activate phospholipase C (PLC). Activation of PLC catalyzes the 




on the endoplasmic reticulum and leads to the release of calcium into the cytosol. DAG activates 
the protein kinase C (PKC) cascade (Barnes and Sharp 1999, Raote, Bhattacharya et al. 2007). 
Through activation of the 5-HT2A/Gαq/11 pathway, transamidation of small G proteins such as 
Rac1, RhoA, and Rab4 can occur (Walther, Peter et al. 2003, Dai, Han et al. 2008, Muma and Mi 
2015).  
Separate from the Gαq/11 pathway, 5-HT2A activates phospholipase A2 (PLA2) and 
arachidonic acid (AA) (Berg, Clarke et al. 1994, Berg, Maayani et al. 1998). Activation of the 
PLA2/AA pathway can occur through 5-HT2A/Gαi/o mediated Ras-Raf-MEK-ERK signaling or 
through 5-HT2A/ Gα12/13 mediated RhoA-MAPK phosphorylation of PLA2 (Kurrasch-Orbaugh, 
Parrish et al. 2003, Kurrasch-Orbaugh, Watts et al. 2003). 5-HT2A receptors have also been 
linked to changes in nitric oxide, calmodulin, CREB, and Akt (Miller, Mariano et al. 1997, Van 
de Kar, Javed et al. 2001).  
In skeletal muscle, vascular smooth muscle (VSM), and neuronal cells, the 5-HT2A 
receptor activates janus kinase (JAK) and signal transducer and activator of transcription (STAT) 
signaling pathways (Guillet-Deniau, Burnol et al. 1997, Banes, Shaw et al. 2005, Singh, Shi et al. 
2007). There are four members of the JAK family (JAK1, JAK2, JAK3, and TYK2) and seven 
members of the STAT family (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6) 
(Aaronson and Horvath 2002). JAK/STAT signaling pathways can be activated through 
cytokines such as interferon and interleukin or GPCRs. JAKs recruited by the receptor 
autophosphorylate and bind to SH2 domains of STATs. The STATs are tyrosine-phosphorylated 
by the JAK and form dimers. The STAT dimers translocate to the nucleus and regulate the 
transcription of certain genes. 5-HT2A receptors have been reported to interact with JAK1, 




serotonin stimulates JAK2/STAT3 via the 5-HT2A receptor; in VSM, 5-HT2A interacts with 
JAK1, JAK2, and STAT1; and in neurons the 5-HT2A receptor stimulates JAK2/STAT3 
(Guillet-Deniau, Burnol et al. 1997, Banes, Shaw et al. 2005, Singh, Shi et al. 2007).  
Functional Selectivity of 5-HT2A Receptors 
 Functional selectivity describes the ligand-dependent selectivity for different signaling 
pathways for a receptor (Kenakin 1995, Kenakin 2001). There are several receptors such as the 
u-opioid receptor, β2-adrenergic, V2 vasopressin, and dopamine receptors that show functional 
selectivity (He, Fong et al. 2002, Urban, Clarke et al. 2007). The 5-HT2A receptor was first 
investigated as functionally selective after it was discovered that the hallucinogenic effects of 
lysergic acid diethylamide (LSD), which binds the 5-HT2A receptor, did not correlate to the 
known effects of 5-HT2A/Gαq/11 signaling (Muschamp, Regina et al. 2004, Urban, Clarke et al. 
2007). The functional selectivity of 5-HT2A receptors plays a role in receptor regulation, 
internalization, recycling, and dimerization and can depend on ligand, G-proteins, cell type, 
receptor expression, and structural conformation. 5-HT2A receptors independently activate the 
5-HT2A/Gαq/11 and the 5-HT2A/PLA2 pathways depending on the ligand structure (Kurrasch-
Orbaugh, Watts et al. 2003, Moya, Berg et al. 2007). Different ligands such as serotonin, 
dopamine, DOI, and clozapine cause internalization of the 5-HT2A receptor at different rates 
(Raote, Bhattacharyya et al. 2013). Depending on cell type, the 5-HT2A receptor selectively 
activates different isoforms of JAK/STATs (Guillet-Deniau, Burnol et al. 1997, Banes, Shaw et 
al. 2005, Singh, Shi et al. 2007).  
Statement of Purpose 
 Schizophrenia affects approximately 1% of the population and there is no cure for the 




symptoms for many patients without the detrimental extrapyramidal side effects and has slightly 
improved the management of negative and cognitive symptoms, there are still many 
schizophrenic patients that are suffering from negative and cognitive symptoms (Buckley and 
Stahl 2007, Goldberg, Goldman et al. 2007). For some patients, the risk of the side effects deters 
them from using antipsychotics. Therefore, there is a demand for improved antipsychotics that 
address the negative and cognitive symptoms, as well as reduce the side effects associated with 
antipsychotics.  
Since the 5-HT2A receptor has been implicated in the mechanism of action of atypical 
antipsychotics, it has been hypothesized that the 5-HT2A receptor may play a role in the 
improvement of negative and cognitive symptoms seen in some patients taking atypical 
antipsychotics. There have been several studies focusing on the binding and effects of atypical 
antipsychotics such as olanzapine and clozapine of the 5-HT2A receptor (Kasper, Hale et al. 
1999, Willins, Berry et al. 1999). Atypical antipsychotics act as antagonists of 5-HT2A/Gαq/11 
pathway and it was considered for some time that this could be contributing to the therapeutic 
effect (Kasper, Hale et al. 1999).  
However, our laboratory found that olanzapine and clozapine not only blocked 5-
HT2A/Gαq/11 signaling, but also activated the JAK2/STAT3 pathway in neuronal cells (Muma, 
Singh et al. 2007, Singh, Shi et al. 2007, Singh, Dai et al. 2009). Previously, the 5-
HT2A/JAK/STAT signaling pathway had only been studied in skeletal muscle and VSM using 
5-HT to stimulate the JAK/STAT pathway. This novel signaling pathway in neuronal cells 
illustrates that atypical antipsychotics are functionally selective at the 5-HT2A receptor by 
antagonizing 5-HT2A/Gαq/11 signaling and activating 5-HT2A/JAK2/STAT3. The long term goal 




understand how atypical antipsychotics produce a therapeutic effect and improve the treatment 
for schizophrenia. Therefore the purpose of this study is to identify functionally selective ligands 
of the 5-HT2A receptor.  
In order to study the 5-HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 pathways separately, we 
need to identify ligands that are functionally selective for the 5-HT2A receptor. Olanzapine 
activates the 5-HT2A/JAK2/STAT3 pathway but antagonizes 5-HT2A/Gαq/11. Ketanserin, a 5-
HT2A receptor antagonist, blocks both 5-HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 pathways 
(Banes, Shaw et al. 2005). Therefore, we are using analogs of ketanserin and olanzapine to 
identify ligands that can be used to study the two pathways independently in the future. To study 
the 5-HT2A/Gαq/11 pathway, we used an intracellular calcium assay. After treatment with the 
ligand, increases in intracellular calcium can be used as an index of activation of the 5-
HT2A/Gαq/11 pathway, while in decrease in DOI-induced intracellular calcium is indicative of 
antagonism of the 5-HT2A/Gαq/11 pathway. To study the 5-HT2A/JAK2/STAT3 pathway, we 
used immunoblotting for phospho-JAK2. Activation of 5-HT2A/JAK2/STAT3 pathway by a 
ligand is indicated by an increase in phosphorylated JAK2, while antagonism of the 5-
HT2A/JAK2/STAT3 pathway is indicated by decreased olanzapine-stimulated phosphorylation 





Chapter 2: Materials and Methods 
Drugs 
Olanzapine and ketanserin-tartrate were purchased from Tocris Bioscience. Olanzapine 
was dissolved in 20% glacial acetic acid to make a 6mM stock solution and the pH was adjusted 
to 6.5 by using 10M NaOH. 6mM olanzapine was then diluted in media to a final concentration 
of 600nM. A stock solution of 2mM ketanserin was made in water. 2mM ketanserin was diluted 
in media or Kreb’s medium to a final concentration of 10nM. DOI (2,5-dimethoxy-4-
iodoamphetamine HCl) was purchased from Sigma. DOI was made up in water for a 6mM stock 
solution and diluted Kreb’s medium to a final concentration of 12uM. Analogs of olanzapine and 
ketanserin were selected by Dr. Prisinzano’s laboratory. 10mM stock solutions of the analogs 
were prepared in 100% DMSO and stored at 4C and then diluted in water to 1mM, immediately 
prior to use.  
Drug Treatments 
In previous studies, 10nM ketanserin was used to antagonize 5-HT2A signaling through 
both 5-HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 (Banes, Shaw et al. 2005). Since the analogs 
were based on the structure of ketanserin, the analogs were tested at 1nM, 10nM, and 100nM 
concentrations. The 1mM stock solutions of analogs were diluted in Kreb’s medium or cell 
culture media for final treatments. For the calcium mobilization assay, the baseline fluorescence 
was recorded for 30 seconds at 10 second intervals. Then the vehicle, DOI, or analogs were 
injected into the plate and the fluorescence response was recorded for 2 minutes at 10 second 
intervals to evaluate an intracellular calcium response. For the analogs that increased calcium 
mobilization, I determined whether the analogs are causing the response via the 5-HT2A 




that did not increase calcium mobilization, I determined whether the analogs could be 
antagonists of the 5-HT2A receptor by pretreatment with the analogs for 30 minutes and then 
stimulated with 12 µM DOI to investigate if the analog could block the DOI-induced increase in 
intracellular calcium.  
For JAK2 phosphorylation assay, cells were treated with vehicle, olanzapine, or analogs 
for 24 hours before the assay was performed to investigate agonism of the 5-
HT2A/JAK2/STAT3 pathway. For analogs that increased phosphorylation of JAK2, 30 minute 
pretreatment with ketanserin was used to block the analog induced phosphorylation of JAK2 in 
order to determine if the increase of phosphorylated JAK2 was due to activation of the 5-HT2A 
receptor. For analogs that did not produce an increase in phosphorylation of JAK2, the cells were 
pretreated with the analog for 30 minutes and then treated with olanzapine for 24 hours to 
determine whether any of the analogs could antagonize the olanzapine induced activation of the 
5-HT2A/JAK2/STAT3 pathway.  
Cell Culture  
Clu119 cells, purchased from Cellutions Biosystems (Burlington, NC), are an embryonic 
mouse hypothalamus cell line that expresses 5-HT2A receptors. Clu119 cells were grown in 
Dulbecco’s modified Eagle’s medium containing glucose, L-glutamine, and sodium bicarbonate, 
with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin. Cells were grown at 37°C 
with 5% CO2.  All cells were grown in 10% charcoal-treated FBS to reduce the serotonin in the 
medium for 48 hours prior to being treated with drugs, harvested, or used in calcium 




Calcium Mobilization Assay 
The calcium mobilization assay is a fluorescence based assay that utilizes Fura-2 AM as 
an index of intracellular calcium concentration. Activation of the 5-HT2A/Gαq/11 pathway leads 
to activation of PLC which catalyzes the formation of IP3. IP3 binds to the IP3 receptor on the 
endoplasmic reticulum and leads to the release of calcium into the cytosol. When the calcium is 
released from the endoplasmic reticulum, it will bind to the Fura-2 AM and create a fluorescent 
response.  
Cells were split into black-sided, clear bottom, 96-well plates. Cell were washed twice 
with 200µl Kreb’s medium (135 mM NaCl, 5.9 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 11.5 
mM D-glucose, 11.6 mM Hepes, pH 7.3) and then incubated with 200µl loading buffer (5 µM 
Fura-2 AM, 0.1% bovine serum albumin, and 0.02% Pluronic F127 in Kreb’s medium) for 1hr at 
37°C in the dark. Loading buffer was removed and cells were washed 2 times with 200µl Kreb’s 
medium. The cells were then pretreated with drugs or Kreb’s medium for 30 minutes at 37°C in 
the dark. The medium was replaced with 100µl fresh Kreb’s medium. The plate was then placed 
in the BioTek Synergy 2 plate reader for injections of test compounds. The ratio of Fura-2 
fluorescence at 340nm to 380nm excitation was measured using the BioTek Synergy 2 
fluorescence plate reader. The background fluorescence was subtracted and this calculation was 
used as an index of intracellular calcium concentration. The area under the curve was calculated 
for all of the data points for 2 minutes and used to compare calcium mobilization. 
JAK2 Phosphorylation Assay 
 To investigate the 5-HT2A/JAK2/STAT3 pathway, western blotting was performed using 
a phospho-JAK2 and total JAK2 antibodies as an index of activation of the 5-





Cells were grown in 10cm plates and then harvested and separated into membrane and 
cytosolic fractions. Cells were collected in hypotonic buffer (0.25M sucrose, 50mM Tris-HCl, 
5mM EDTA, 100mM NaCl, protease inhibitor cocktail, and phosphatase inhibitors). The cell 
lysate was sonicated to homogenize the samples and then spun down at 25000xg for 1hr at 4°C 
to collect the supernatant containing the cytosolic fraction and pellet the membrane fraction. The 
membrane fraction pellet was reconstituted using solubilization buffer (20mM Tris, 1mM 
EDTA, 100mM NaCl, 1% sodium cholate, protease inhibitor cocktail, and phosphatase 
inhibitors) and sonicated to break up the pellet. The centrifuge tubes were shaken horizontally 
for 1hr at 4°C. The homogenate was then centrifuged at 25000xg for 1hr at 4°C. The supernatant 
containing the membrane fraction was then collected, aliquoted, and stored at -80°C. 
Western Blotting 
A bicinchoninic acid assay was used to determine the total concentration of protein in 
each sample. Equal amounts of proteins of the membrane fractions were separated on 10% SDS-
PAGE gels at 150V and transferred to polyvinylidene fluoride membranes at 100V for 2hrs. The 
membranes were incubated in 5% non-fat milk made in Tris-buffered saline, 0.1% Tween-20 
(TBST) at room temperature for one hour to block non-specific binding. The membranes were 
then incubated in anti-JAK2 (1:1000, monoclonal antibody, #04-001, EMD Millipore, USA) 
overnight at 4°C. After washing 4 times for 10 minutes with TBST, the membranes were 
incubated in goat-anti-mouse secondary antibody (1:10000, #119380, Jackson ImmunoResearch, 
USA) at room temperature for 1hr. The membranes were washed 4 times for 10 minutes with 
TBST. The membranes were incubated with ECL, a chemiluminescence solution, (Cat# 




chemiluminescent signal was captured using BioRad ChemiDoc XRS+ molecular imager 
(BioRad, USA). 
The membranes were then incubated in 5% bovine serum albumin made in TBST and 
incubated in anti-phospho-JAK2 (1:1500, monoclonal antibody, #3779, Cell Signaling, USA) 
overnight at 4°C. Membranes were washed 3 times for 5 minutes with TBST and incubated in 
goat-anti-rabbit secondary antibody (1:10000, #120745, Jackson Immuno Research, USA) at 
room temperature for 1hr. The membrane was washed 3 times for 5 minutes and membranes 
were incubated with ECL and the data collected as described above.  
The membranes were then incubated in anti-β-actin antibody (1:20000, #ICN691001, MP 
Biomedicals) for 30 minutes and washed 3 times for 10 minutes with TBST. The membranes 
were incubated in goat-anti-mouse antibody for an hour at room temperature and washed 3 times 
for 10 minute. The membranes were incubated with ECL reagent and the luminescence was 
detected.   
The integrated optical density (IOD) of the bands was quantified and analyzed using 
ImageLab 3.0 software (BioRad, USA) and the pJAK2 was normalized to JAK2.  
Data Analysis and Statistics  
GraphPad Prism 5.0 (GraphPad Software Inc., USA) was used for all statistical analyses. 
A probability level of p<0.05 was considered to be statistically significant. For the calcium 
assay, AUC data was analyzed by a one-way ANOVA and presented as the mean ± the standard 
error of the mean. The data was then analyzed using the Tukey’s post hoc test. For the JAK2 




analyzed by a one-way ANOVA. The data was then analyzed using the Tukey’s or Dunnett’s 





Chapter 3: Results 
 Previously, our laboratory reported that olanzapine stimulated the 5-HT2A/JAK2/STAT3 
pathway in rat frontal cortex, rat hypothalamus, and an embryonic rat cortical neuronal cell line, 
A1A1v cells (Muma, Singh et al. 2007, Singh, Dai et al. 2009). My initial studies focused on 
determining if Clu119 cells, an embryonic mouse hypothalamus cell line, could be used for 
studying the 5-HT2A/JAK2/STAT3 pathway. Clu119 cells express 5-HT2A receptors, STAT3, 
and JAK2, as well as Gαq/11 proteins and other downstream effectors of the 5-HT2A/Gαq/11 
pathway (CedarLane, Burlington, NC). The calcium mobilization assay was used as an indicator 
of 5-HT2A/Gαq/11 signaling because the release of intracellular calcium from the endoplasmic 
reticulum is a result of downstream effectors from Gαq/11 proteins coupling to 5-HT2A receptors 
(Raote, Bhattacharya et al. 2007, Paredes, Etzler et al. 2008). Previous studies have reported that 
DOI increases calcium mobilization via the 5-HT2A receptor and that this increase could be 
blocked by ketanserin (Hoyer, Clarke et al. 1994, Dai, Dudek et al. 2011). Clu119 cells were 
treated with vehicle or 12uM DOI, with or without a 30 minute pretreatment with 10nM 
ketanserin (Fig. 1A).  An area under the curve (AUC) analysis of the fluorescence ratio over time 
indicates that 12uM DOI significantly increased calcium mobilization and pretreatment with 
ketanserin blocked the DOI-induced calcium mobilization (Fig. 1B). Immunoblotting was used 
to investigate the phosphorylation of JAK2 as an indicator of 5-HT2A/JAK2/STAT3 signaling. 
Cells were treated with 600nM olanzapine for 24 hours. Treatment with olanzapine induced 
phosphorylation of JAK2 which was blocked with 30 minute pretreatment with 10nM ketanserin 





 Analogs that are structurally similar to olanzapine and ketanserin were selected from a 
library to investigate functional selectivity of the 5-HT2A receptor. SCAP109608 (608), 
SCAP109609 (609), SCAP109610 (610), SCAP109615 (615), and SCAP109618 (618) were the 
five analogs selected to determine their effects on both the 5-HT2A/Gαq/11 and 5-
HT2A/JAK2/STAT3 pathways. The analogs were tested at three different concentrations: 1nM, 
10nM, and 100nM. These concentrations were selected based on previous experiments that 
demonstrated that ketanserin blocked 5-HT2A receptor signaling at the 10nM concentration 
(Banes, Shaw et al. 2005).  
Identifying Agonists of the 5-HT2A/Gαq/11 Pathway 
 Clu119 cells were plated in 96 well plates and treated with Fura-2-AM, which binds to 
intracellular calcium and produces a fluorescent signal. The cells were then treated with 1nM, 
10nM, and 100nM concentrations of 608, 609, 610, 615, and 618. AUC analysis indicates there 
was no significant difference between treatments of 608 and the vehicle (Fig 2A & 2B). 
Treatment of the cells with 10nM 610 caused significantly increased intracellular calcium 
compared to the vehicle. There was no significant difference between the vehicle and treatment 
with 1nM and100nM 610. Pretreatment with ketanserin significantly reduced the calcium 
response to 10nM 610 (Fig. 2C & 2D). There was a significant increase in intracellular calcium 
when cells were treated with 1nM and 100nM 618. However, there was no significant decrease 
when cells were pretreated with ketanserin and then treated with 100nM 618 (Fig. 2E & 2F). 
Treatment with 609 and 615 did not induce calcium mobilization (Fig. 3A, 3C, 3E, & 3G).  
Identifying Antagonists of the 5-HT2A/Gαq/11 Pathway 
 Neither 609 nor 615 increased the fluorescence ratio which indicates that neither activate 




antagonize the 5-HT2A/Gαq/11 pathway. Clu119 cells were pretreated with 100nM of 609 or 615 
and then stimulated with DOI to determine if either analog could block DOI-induced calcium 
mobilization (Fig. 3B & 3F). AUC analysis indicates that both 609 and 615 significantly reduced 
the DOI-induced calcium mobilization (Fig. 3D & 3H).  
Effect of Analogs on the 5-HT2A/JAK2/STAT3 Pathway 
Clu119 cells were treated with 1nM, 10nM, 100nM conentrations of 608, 609, 610, 615, 
618, vehicle, or 600nM olanzapine for 24 hours before harvesting. Antibodies for both pJAK2 
and JAK2 were used to analyze the treatment effect. The bar graphs represent the quantification 
of pJAK2 divided by the JAK2. After 24 hours treatment with 100nM 608, pJAK2 was 
significantly increased compared to the vehicle, but there was no significant increase with 1nM 
or 10nM 608. Pretreatment with ketanserin did not significantly decrease the stimulation of 
pJAK2 by 100nM 608 (Fig 4A). Treatment with 1nM 610 significantly increased pJAK2 
compared to the vehicle, but there was no significant increase with 10nM or 100nM 610. 
Pretreatment with ketanserin did not significantly decrease the 1nM 610 stimulation of pJAK2 
(Fig 4B). 1nM 618 significantly increased pJAK2 compared to vehicle and when experiments 
were repeated with pretreatment with vehicle or ketanserin, 10nM 618 also significantly increaed 
pJAK2. There was no signficant antagonization of 10nM 618 when pretreated with ketanserin 
(Fig 4C). When the cells were pretreated with vehicle or ketanserin and then treated with 10nM 
609, treatment with 10nM 609 significantly increased pJAK2. Pretreatment with ketanserin 
significantly reduced the 10nM 609 stimulated increase of pJAK2 (Fig 5A). Treatment with 615 
did not increase pJAK2. Therefore, we investigated the posibility that 615 could be an antagonist 




and then treated with 600nM olanzapine for 24 hours. Pretreatment with 100nM 615 





Figure 1: DOI stimulates the 5-HT2A/Gαq/11 and olanzapine stimulates the 5-
HT2A/JAK2/STAT3 pathway in Clu119 cells. A Clu119 cells were treated with vehicle or 12uM 
DOI, with or without 10 nM ketanserin pretreatment. B For AUC, one-way ANOVA indicates 
significance between treatments [F(3,8)= 7.793; p<0.01]. Tukey’s post hoc analysis reports 




12uM DOI. C Cells were pretreated with vehicle or 10nM ketanserin for 30 minutes and then 
treated with vehicle or 600nM olanzapine for 24 hours. One-way ANOVA indicates significance 
between treatment [F(3,14)=8.980; p<0.005]. Tukey’s post hoc analysis reports *p<0.005 
between vehicle/vehicle and vehicle/600nM olanzapine and #p<0.01 between vehicle/600nM 










Figure 2: Effect of analogs through the 5-HT2A/Gαq/11 pathway. Clu119 cells were treated with 
vehicle or analogs and changes in 340/380nm fluorescence ratio were recorded for 2 minutes. 
Graphs represent mean of each data set and the mean ± the standard error of the mean of the area 
under the curve (n=3). The arrow represents the time of injection (30 seconds). A Cells were 
treated with 1nM, 10nM, and 100nM concentrations of 608, vehicle, and pretreatment with 
10nM ketanserin, followed by treatment with 100nM 608. B For the AUC, there was no 
significant difference between treatments [F(4,10)=1.992; p=0.171]. C Cells were treated with 
1nM, 10nM, and 100nM concentrations of 610, vehicle and pretreatment with ketanserin, 
followed by treatment with 10nM 610. D For the AUC, one-way ANOVA indicates that there is 
a significant difference between treatments [F(4, 10)=6.684; p<0.01] and Tukey’s post hoc test 
reported *p<0.05, n=3 between vehicle and 10nM 610 and #p<0.05, n=3 between 10nM 610 and 
10nM Ket/10nM 610. E Cells were treated with 1nM, 10nM, and 100nM concentrations of 618, 
vehicle and pretreatment with ketanserin, followed by treatment with 100nM 618. F For the 
AUC, one-way ANOVA indicates that there is a significant difference between treatments [F(4, 
10)=3.779; p<0.05] and Tukey’s post hoc test reported *p<0.05, n=3 between vehicle and 1nM 








Figure 3: Effect of analogs through the 5-HT2A/Gαq/11 pathway and DOI-induced calcium 
mobilization. Clu119 cells were treated with vehicle or analogs and changes in 340/380nm 
fluorescence ratio were recorded for 2 minutes. The arrow represents the time of injection (30 
seconds). Graphs represent the mean ± the standard error of the mean of the area under the curve 
(n=3). A Cells were treated with 1nM, 10nM, and 100nM 609, or vehicle. B Cells were treated 
with vehicle, 100nM 609, and 12µM DOI; with and without pretreatment with 100nM 609. C 
AUC analysis indicates no significant differences between 1nM, 10nM, 100nM 609 and vehicle. 
D For AUC analysis, one-way ANOVA indicates that there is a significant difference between 
treatment groups [F(3, 8)=10.47; p<0.005] and Tukey’s post hoc test reported **p<0.01, n=3 for 
12uM DOI treatment compared to vehicle and ##p<0.01, n=3 for 100nM 609/12uM DOI 
compared to 12uM DOI. E Cells were treated with 1nM, 10nM, and 100nM 615. F Cells were 
injected with vehicle, 100nM 615, and 12µM DOI; with and without pretreatment with 100nM 
615. G AUC analysis indicates no significant differences between 1nM, 10nM, 100nM 615 and 
vehicle. H For AUC analysis, one-way ANOVA indicates significance between treatment groups 
[F(3, 8)=11.07; p<0.005] and Tukey’s post hoc test reported **p<0.01, n=3 for 12uM DOI 














Figure 4: Effect of analogs through the 5-HT2A/JAK2/STAT3 pathway. Clu119 cells were 
treated with vehicle or analogs for 24 hours or pretreated with vehicle or ketanserin for 30 
minutes and then treated with vehicle or analogs for 24 hours. Antibodies for both pJAK2 and 
JAK2 were used to analyze the results. The bar graphs represent the mean quantification of 
pJAK2 divided by the JAK2 (n=3). A Cells were treated with 1nM, 10nM, and 100nM 
concentrations of 608, olanzapine, or vehicle for 24 hours (left) or cells were pretreated with 
vehicle or ketanserin for 30 minutes and then treated with vehicle or 100nM 608 (right). For the 
left graph, one-way ANOVA indicates that there is a significant difference between treatment 
groups [F(3, 14)=4.717; p<0.05] and Dunnett’s post hoc test reported **p<0.01 for 100nM 608 
compared to vehicle. B Cells were treated with 1nM, 10nM, and 100nM concentrations of 610, 
or vehicle for 24 hours (left) or cells were pretreated with vehicle or ketanserin for 30 minutes 
and then treated with vehicle or 1nM 610 (right). For the left graph, one-way ANOVA indicates 
that there is a significant difference between treatment groups [F(4, 13)=3.387; p<0.05] and 
Dunnett’s post hoc test reported *p<0.05, n=3 for 1nM 610 treatment compared to vehicle. C 
Cells were treated with 1nM, 10nM, and 100nM concentrations of 618, or vehicle for 24 hours 
(left) or cells were pretreated with vehicle or ketanserin for 30 minutes and then treated with 
vehicle or 10nM 618 (right). For the left graph, one-way ANOVA indicates that there is a 
significant difference between treatment groups [F(4, 8)=7.756; p<0.01] and Dunnett’s post hoc 
test reported **p<0.005, n=2 for 10nM 610 treatment compared to vehicle. For the right graph, 
one-way ANOVA analysis indicates a significant difference between treatment groups 
[F(2,5)=6.910; p<0.05] and Tukey’s post hoc test reported *p<0.05, n=3 for vehicle/10nM 618 








Figure 5: Effect of analogs through the 5-HT2A/JAK2/STAT3 pathway. Clu119 cells were 
treated with vehicle or analogs for 24 hours or pretreated with vehicle or ketanserin for 30 
minutes and then treated with vehicle or analogs for 24 hours. Antibodies for both pJAK2 and 
JAK2 were used to analyze the results. The bar graphs represent the mean quantification of 
pJAK2 divided by the JAK2 (n=3). A Cells were treated with 1nM, 10nM, and 100nM 
concentrations of 609, or vehicle for 24 hours or cells were pretreated with vehicle or ketanserin 
for 30 minutes and then treated with vehicle or 10nM 609. For the right graph, one-way ANOVA 
analysis indicates a significant difference between treatment groups [F(2,5)=9.957; p<0.05] and 
Tukey’s post hoc test reported *p<0.05, n=3 for vehicle/10nM 609 compared to vehicle/vehicle 
and #p<0.05, n=3 for vehicle/10nM 609 compared to 10nM ketanserin/10nM 609. B Cells were 
treated with 1nM, 10nM, and 100nM concentrations of 615, or vehicle for 24 hours or cells were 
pretreated with vehicle or 100nM 615 for 30 minutes and then treated with vehicle or 600nM 
olanzapine. One-way ANOVA analysis of the pretreatment with 100nM 615 indicates a 
significant difference between treatment groups [F(3,7)=6.852; p<0.05]. Tukey’s post hoc test 
reported *p<0.05, n=3 for vehicle/600nM olanzapine compared to vehicle/vehicle and #p<0.05, 





Chapter 4: Discussion  
GPCRs such as serotonin, μ-opioid, β2-adrenergic, angiotensin receptors, V2 
vasopressin, and dopamine receptors, have become targets for drug discovery, because ligands 
are often functionally selective at these receptors (Mottola, Laiter et al. 1996, Yu, Zhang et al. 
1997, He, Fong et al. 2002). Targeting specific signaling pathways through a receptor can lead to 
more effective treatment options and possibly lead to a better understanding of different 
disorders. FDA approved drugs often target members of a GPCR gene family, because GPCRs 
can couple to multiple G-proteins, arrestins, or other downstream effectors (Rankovic, Brust et 
al. 2016).  These pathways can often be pharmacologically separated and therefore are being 
explored as new possibilities for GPCR-targeted drug discovery (Marti-Solano, Iglesias et al. 
2015, Rankovic, Brust et al. 2016).  
For example, ‘beta-blockers’, commonly used to treat myocardial infarction , are 
typically antagonists for β-adrenergic receptors, which couple to Gαs-proteins, but also activate 
ERK  signaling through β-arrestins (Azzi, Charest et al. 2003, Kenakin 2011, Whalen, Rajagopal 
et al. 2011).  Angiotensin type 1 receptors are drug targets for treating hypertension and 
cardiovascular disorders. Certain drugs are unable to activate receptor coupling to G-proteins, 
but can also activate ERK phosphorylation through β-arrestins (Wei, Ahn et al. 2003). However, 
sometimes functionally selective ligands used to treat disorders can lead to unwanted side 
effects. Famotidine targets the histamine H2 receptor to treat gastrointestinal ulcers by acting as 
an inverse agonist for Gs-protein activation of adenylyl cyclase. Famotidine also activates the 
expression of histidine decarboxylase independently of Gs-proteins that lead to a rebound of acid 
hypersecretion after withdrawal (Alonso, Zappia et al. 2015). Therefore, there is still a need for 




This is also true for using atypical antipsychotics for the treatment of schizophrenia. 
Atypical antipsychotics have previously been reported to antagonize the 5-HT2A/Gαq/11 
signaling pathway and that this effect could contribute to improving management of the 
symptoms of schizophrenia (Meltzer, Li et al. 2003, Amato 2015). Our lab found that, in addition 
to antagonizing 5-HT2A/Gαq/11, atypical antipsychotics olanzapine and clozapine also activate 
the 5-HT2A/JAK2/STAT3 pathway (Singh, Shi et al. 2007, Singh, Dai et al. 2009). Therefore, 
we are investigating the functional selectivity of ligands of the 5-HT2A receptor in order to 
better understand the effect of atypical antipsychotics at the 5-HT2A receptor and provide 
avenues of investigation for creating more effective treatments for schizophrenia. In the future, 
we hope to identify compounds that either antagonize 5-HT2A/Gαq/11 signaling or activate 5-
HT2A/JAK2/STAT3 signaling independently. These compounds can be used to study how 
atypical antipsychotics are producing a therapeutic effect for positive, negative, and cognitive 
symptoms.  
Our lab used analogs of olanzapine and the 5-HT2A receptor antagonist ketanserin based 
on the previous data that olanzapine exhibited functional selectivity at the 5-HT2A receptor and 
ketanserin acts as an antagonist to both 5-HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 pathways 
(Banes, Shaw et al. 2005, Singh, Shi et al. 2007). Analogs SCAP109608, SCAP109609, 
SCAP109610, SCAP109615, and SCAP109618 were tested to determine how they effected the 
5-HT2A/Gαq/11 and 5-HT2A/JAK2/STAT3 pathways.  
Using the calcium mobilization assay, we identified three analogs that induced calcium 
mobilization and two analogs that prevented 5-HT2A receptor agonist-induced calcium 
mobilization. 608 did not significantly increase calcium mobilization, but both 1nM and 10nM 




10nM, but not at 100nM. Ketanserin blocked the effect by 10nM 610, indicating that 610 is 
activating the 5-HT2A/Gαq/11 pathway. 5-HT2A receptors internalize when over stimulated, so it 
is possible that 100nM 610 is desensitizing the 5-HT2A receptors or has a toxic effect at this 
dosage (Raote, Bhattacharyya et al. 2013). 618 induced calcium mobilization at 1nM and 
100nM. A more extensive dose response experiment with more replications should be done to 
determine the most effective concentration that 618 induces calcium mobilization, as well as to 
see if ketanserin can effectively block 618. However, the decrease in calcium mobilization after 
pretreatment with ketanserin and then treatment with 100nM 618 is not significant. Although 
treatment with 618 induced a significant increase in calcium mobilization, the increase was 
small, which may indicate that 618 is a partial agonist. This could account for why pretreatment 
with ketanserin did not significantly block the effects of 618. A higher dose of ketanserin could 
be used or an increase of replicates could help to determine if 618 is acting through the 5-HT2A/ 
Gαq/11 pathway. Analogs 609 and 615 did not induce calcium mobilization over the vehicle. 
Therefore, we used these analogs to pretreat the cells for 30 minutes before DOI treatment. Both 
609 and 615 significantly reduced the DOI- induced calcium mobilization, indicating that these 
analogs block the 5-HT2A/Gαq/11 pathways.  
Using immunoblotting to study the phosphorylation of JAK2, we identified four analogs 
that stimulated phosphorylation of JAK2 and one analog that prevented 5-HT2A receptor 
agonist-induced phosphorylation of JAK2. 100nM 608, 1nM 610, and 1nM and 10nM 618 
significantly increased phosphorylated JAK2 over that of the vehicle, but pretreatment with 
ketanserin did not significantly reduce the phosphorylation of JAK2. There is a trend that 
ketanserin may be reducing the analog induced phosphorylation of JAK2, so more replicates are 




HT2A/JAK2/STAT3 pathway. There is very little response with 1nM and 10nM 608, so 
concentrations higher than 100nM should be investigated and then ketanserin should be used to 
determine if phosphorylation of JAK2 is occurring through the 5-HT2A receptor. On the other 
hand, both 610 and 618 were more effective at the lower concentration, so these analogs should 
be investigated at lower concentrations. 10nM 609 significantly increased phosphorylation of 
JAK2 and this increase was blocked by ketanserin, indicating that the response by 609 is due to 
the 5-HT2A/JAK2/STAT3 receptor. 615 did not increase the phosphorylation of JAK2, but when 
cells were pretreated with 100nM 615 and then treated with olanzapine, the increase in 
phosphorylated JAK2 was significantly reduced, indicating that 615 is an antagonist of the 5-






















Increase # Yes # _____ Increase Yes # _____ 
SCAP109609 
“609” 
No Effect _____ Yes Increase Yes _____ 
SCAP109610 
“610” 
Increase Yes _____ Increase Yes # _____ 
SCAP109615 
“615” 
No Effect _____ Yes No Effect _____ Yes 
SCAP109618 
“618” 
Increase Yes # _____ Increase Yes # _____ 
 
Table 1: Summary of the effects of the analogs on both the calcium mobilization assay and 
immunoblotting for JAK2 phosphorylation. The ability of the effect of each analog to either be 
antagonized by ketanserin or antagonize the stimulation by a known 5-HT2A receptor agonist is 





Like olanzapine and clozapine, 609 antagonizes the 5-HT2A/Gαq/11 pathway, but 
activates the 5-HT2A/JAK2/STAT3 pathway. This study found that ketanserin and 615 
antagonize olanzapine-induced phosphorylation of JAK2 in Clu119 cells. Before this study, 
ketanserin was a known antagonist of the 5-HT2A/Gαq/11 pathway and 5-HT2A/JAK2/STAT3 in 
vascular smooth muscle (Banes, Shaw et al. 2005). 610 is an agonist of the 5-HT2A/Gαq/11 
pathway and is a potential agonist of the 5-HT2A/JAK2/STAT3 receptor. Based on the results, a 
concentration between 10nM and 100nM 610 may activate that 5-HT2A/Gαq/11 pathway, but not 
affect the 5-HT2A/JAK2/STAT3 pathway. 608 and 618 increase calcium mobilization and 
phosphorylation of JAK2, but were not significantly blocked by ketanserin. If these analogs are 
not acting through the 5-HT2A receptor, they could be acting through other receptors that 
activate JAK/STAT signaling, including type II cytokine receptors, interleukin receptors, 
erythropoietin receptors, and thrombopoietin receptors (Rawlings, Rosler et al. 2004, Nicolas, 
Amici et al. 2013). 
Previously, compounds with similar structures, such as the class of 
phenylisopropylamines, have shown functional selectivity of the 5-HT2A receptor (Kurrasch-
Orbaugh, Watts et al. 2003, Moya, Berg et al. 2007). DOI, 2,5-dimethoxy-4-methyl (DOM), and 
4-bromo-2,5-dimethoxyphenylisopropylamine (DOB) differentially activate the 5-HT2A/Gαq/11 
or 5-HT2A/PLA2/AA pathways (Moya, Berg et al. 2007). DOM preferentially stimulated the 5-
HT2A/PLA2/AA pathway while DON activated the 5-HT2A/Gαq/11. Serotonin activates 5-
HT2A/Gαq/11, 5-HT2A/PLA2/AA, and 5-HT2A/JAK/STAT, while tryptamine is a full agonist for 




(Kurrasch-Orbaugh, Watts et al. 2003). Our data is consistent with these reports that compounds 
with similar structures are functionally selective at the 5-HT2A receptor.  
The 5-HT2A/JAK/STAT pathway has been previously studied in myoblasts from rat 
muscle fibers, vascular muscle cells, cortical cell lines, and rat hypothalamus and frontal cortex 
(Banes, Shaw et al. 2005, Muma, Singh et al. 2007, Singh, Shi et al. 2007). The 5-HT2A/Gαq/11 
pathway has been studied in various regions of the brain and peripheral systems that express 5-
HT2A receptors. We chose to examine the functional selectivity of 5-HT2A receptors in a mouse 
hypothalamic cell line, Clu119, which expresses 5-HT2A receptors, STAT3, and JAK2, but not 
5-HT2C. Clu119 cells also express 5-HT1B, estrogen receptors α and β, insulin-like growth 
factor receptors, brain derived neurotrophic factor (Biosystems). The analogs tested in this 
dissertation should be investigated in primary neurons to corroborate the results presented here.  
In this dissertation, the calcium assay is used to determine action of the analogs on the 5-
HT2A receptors. Other ways of studying the 5-HT2A/Gαq/11 pathway include PLC activity, 
GTPγS binding assay, and IP3 accumulation assay. To be confident that the calcium 
mobilization seen in our experiments was due to 5-HT2A/Gαq/11 signaling, we used ketanserin to 
antagonize 5-HT2A/Gαq/11 signaling. However, a second antagonist should be used to confirm 
selectivity through the 5-HT2A receptors. Also, a second test for 5-HT2A/Gαq/11 signaling, such 
as an IP3 accumulation assay, can be used to confirm the calcium assay data. The GTPγS 
binding assay can be used to investigate the effect the analogs have on 5-HT2A receptors 
coupling with Gαq/11 proteins. 
We used pJAK2 and JAK2 antibodies for immunoblotting to investigate the 5-
HT2A/JAK2/STAT3 pathway. Although in VSM and skeletal muscle the 5-HT2A receptor 




showed that olanzapine induced increased JAK2 and STAT3, but not STAT1 and STAT5 
(Banes, Shaw et al. 2005, Singh, Shi et al. 2007). These differences between cell types is another 
form of functional selectivity, but the analogs should be tested with other JAK/STATs to be 
certain that the 5-HT2A receptor is acting through JAK2/STAT3. Other receptors that can lead to 
activation of JAK/STAT signaling include type II cytokine receptors, interleukin receptors, 
erythropoietin receptors, and thrombopoietin receptors (Rawlings, Rosler et al. 2004, Nicolas, 
Amici et al. 2013). It is not known if any of these receptors are expressed in Clu119 cells, so to 
be certain that the analogs are acting on the 5-HT2A receptor, pretreatment with ketanserin is 
used as a control. 
In the future, more analogs should be tested to gather more information about the 
structure of ligands that can either activate or antagonize the 5-HT2A/Gαq/11 or the 5-
HT2A/JAK2/STAT3 pathways. Based on the data collected, new analogs can be created to 
identify analogs that can be used to study these pathways independently. These analogs can be 
studied in neuronal primary culture to determine the downstream effect of each pathway 
individually. Furthermore, these new analogs can be used in schizophrenic animal models to 
investigate the effect each pathway has on positive, negative, and/or cognitive symptoms and 
possibly if the 5-HT2A receptor has an impact on the side effects of atypical antipsychotics.  
Investigating the functional selectivity of different receptors presents a new way of 
developing and understanding new treatments for a variety of disorders, including schizophrenia. 
Patients have been using atypical antipsychotics for decades with varying responses. 
Understanding how these drugs interact with receptors is important for improving the lives of 
people living with schizophrenia. The analogs tested in this dissertation and those that will be 
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